NasdaqGS:BEAMBiotechs
Beam Therapeutics (BEAM): Evaluating Valuation as Clinical Progress Drives Renewed Investor Focus
Beam Therapeutics (BEAM) is drawing investor attention after delivering updates on multiple clinical-stage programs for genetic diseases. Recent focus centers on BEAM-302 for alpha-1 antitrypsin deficiency and the upcoming BEACON trial data release.
See our latest analysis for Beam Therapeutics.
Shares of Beam Therapeutics have swung sharply in recent weeks, with a 30-day share price return of -17.74%, offset by a strong 90-day rally of 26.05%. This hints at shifting investor sentiment around...